Our CEO Clarissa Sowemimo-Coker will be speaking at HLTH Europe 2024 in a panel discussion on “Eighths and pains: The ongoing trials and tribulations of cannabis in healthcare”.
HLTH Europe 2024 will unite Europe's brightest minds in health. The inaugural event, taking place from 17-20 June in Amsterdam, will connect leaders from over 50 countries from every part of the European health ecosystem.
If you would like to attend, use the code HE24_CLARISSASC for a €150 discount off the ticket price at the point of registration.
Lina Behrens
It is the time to introduce the last (but not least) top expert and our panelist - Joseph Saba. Joseph will also give an interview on access to medicines.
Joseph Saba, MD, is an infectious disease physician working on the frontline of access to healthcare since the early days of the HIV/AIDS
pandemic.
Throughout his career, Joseph has led numerous discussions with pharmaceutical companies, governments and other key players across the healthcare community to drive access to innovative medications in low-to-middle
income countries (LMICs). He is known internationally for establishing the first antiretroviral drug access program through the UNAIDS Drug Access Initiative, making it possible for critical medicines to reach patients in need during the peak of the HIV/AIDS epidemic and pioneering a new generation of treatment access solutions for LMICs.
In 1993, Joseph joined the World Health Organization (WHO) as the WHO Focal Point for the National Plan for HIV Vaccine Development. From 1994-1995, he worked with the WHO Global Program on AIDS in Rwanda and later supported HIV vaccine research efforts in Geneva.
Following his time at WHO, he worked at the Joint United Nations Program on HIV/AIDS in the Department of Policy, Strategy and Research, where he led a global research effort focused on Prevention of Mother-to-Child Transmission (PMTCT) of HIV/AIDS, as well as the roundbreaking PETRA study, a multi-centre clinical trial on PMTCT treatment in Africa.
For the past twenty-three years, Joseph has served as Chief Executive Officer of Axios
International, a healthcare access company he co-founded, which has developed programs to improve patient access to healthcare in more than 100 countries.
As a result of his groundbreaking work in the field of access to healthcare, Joseph was named one of the top 100 Healthcare Leaders 2023 by Forbes Middle East. He has also been featured in various publications, including the Wall Street Journal, BBC, International Herald Tribune,
Newsweek, and Pharmaceutical Executive, among others.
Joseph is the author of Amazon best-seller A World Undivided – A Quest For Better Healthcare Beyond Geopolitics, and his research has been published in more than 40 articles in leading peer reviewed scientific journals.
He completed his medical degree at St. Joseph University (Beirut, Lebanon), and his Infectious
Diseases specialty, along with a certificate of Medical Statistics, at the University Paris VI
(France). Joseph also holds a Master of Communications and Medical Management (MSc) from the Superior Business School (Paris, France). He is fluent in Arabic, French and English.
6 czerwca, podczas konferencji Priorities and Challenges in Polish and European Drug Policy, odbędzie się panel „Digital Health role in patient access to innovative medicines and clinical outcomes improvement”.
Uczestniczyć w nim będą:
– Stefan Gijssels z Patient Expert Center,
– Ozren Pezo,
– Michal Pilkiewicz z IQVIA,
– Joseph Saba.
Sesja, którą moderować będzie Wlodek Kubiak, rozpocznie się o godz. 14:50.
Więcej o #DrugPolicy na stronie internetowej: https://tiny.pl/df9f3.
🎉 Exciting news from Day 1 at HLTH Europe! John Mulcahy our VP of Product at S3 Connected Health, joined a distinguished panel of experts from DiMe’s International Digital Health Regulatory Pathways initiative. They delved into the "Opportunities and Realities of Developing a Multi-Market DHT Evidence and Commercial Approach in Europe.”
HLTH Europe has been a tremendous success, and we're eager to share the valuable insights gained from this session.
#HLTHEurope#DigitalHealth
As we put DIA 2024 in the rearview window, Alira Health is energized by the insights and open-minded discussions that Clients are willing to have, to learn more about everything from Clinical Trial Strategies advancements to how our Alira Health Digital Platform is advancing everything from simple RWE inquiries to Registries to Hybrid/DCTs. Have you listened to any 3rd party insights - for your very expensive clinical development plans?
Sharing another important session at #diaglobal: on Wednesday I am leading a panel discussion on embedding diversity and inclusion in the context of global clinical research programs, and evolving regulator expectations.
Our fantastic panel includes the brilliant Loriana Hernández-Aldama, who will share important and impactful patient insights, as well as regulators leading the charge on this topic, FDA’s Karen Hicks, and Health Canada’s Alysha Croker.
Come join us! Wednesday 19-June at 3:15-4:15 in Room 6F!
#365: Embedding Diversity and Inclusion into Global Clinical Research: Where Have We Been and Where Are We Going?
https://lnkd.in/eCV2Qmst#MSD, #regulatorypolicy, #fdaregulatory, #regulatoryaffairs, #fda, #healthpolicy
🆕 “Manufacturers have to rethink their value narrative, and what their plans for holistic evidence generation are” A conversation with the Value & Access team at Syneos Health. Learn more⬇
https://lnkd.in/eS5KCY9T
🩺 Today the Dutch Parliament will debate the Dutch Global Health Strategy. This strategy is the cornerstone of the Netherlands’ approach to global public health challenges.
We, the Dutch Global Health Alliance, have been closely monitoring the development of this strategy.
As a coalition of 20 civil society organizations, we call on the Dutch Parliament to fully endorse the strategy and give it the political and financial support it needs.
We share several key asks and recommendations to strengthen the strategy:
Increase non-Official Development Assistance contributions to the strategy.
Develop a comprehensive implementation agenda with clear measurable qualitative and quantitative indicators.
Put stringent conditions on government funding for pharmaceutical research, ensuring transparency and affordability.
Ensure that public-private partnerships in healthcare are accompanied by robust regulations that safeguard equity and prioritize the achievement of Sustainable Development Goal 3 on health.
🔗 Read our full position article here https://bit.ly/3VIvn5y#GlobalHealth#HealthForAll#DutchGlobalHealthAlliance
Today, our board member Elena Moya delivered a presentation on why health systems must deliver with patients at Pharma 2024, organised by Reuters Events in Barcelona.
During her presentation, she showcased why patient involvement is non-negotiable when it comes to the success of our healthcare systems. Before diving into technical solutions to strengthen the involvement of the patient community, she emphasised the importance of understanding why patient involvement is so crucial and how it adds value to healthcare systems.
Patients' practical understanding of healthcare systems is essential in developing services that align with their needs. To make this possible, we need to promote a cultural shift in how we interact with patients.
#PatientPerspective
